Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.